Treatment of Paget's disease - Taming the wild osteoclast

被引：17

作者：

Deftos, LJ ^{[1
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] San Diego Vet Affairs Med Ctr, San Diego, CA USA

[3] Calif Western Sch Law, San Diego, CA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 09期

关键词：

D O I：

10.1056/NEJMp058184

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：872 / 875

页数：4

共 5 条

[1]

FLEISCH H, 2002, PRINCIPLES BONE BIOL, V2, P1361

[2] Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].

Lacey, DL ;

Timms, E ;

Tan, HL ;

Kelley, MJ ;

Dunstan, CR ;

Burgess, T ;

Elliott, R ;

Colombero, A ;

Elliott, G ;

Scully, S ;

Hsu, H ;

Sullivan, J ;

Hawkins, N ;

Davy, E ;

Capparelli, C ;

Eli, A ;

Qian, YX ;

Kaufman, S ;

Sarosi, I ;

Shalhoub, V ;

Senaldi, G ;

Guo, J ;

Delaney, J ;

Boyle, WJ .

CELL, 1998, 93 (02) :165-176

[3] Severely suppressed bone turnover: A potential complication of alendronate therapy [J].

Odvina, CV ;

Zerwekh, JE ;

Rao, DS ;

Maalouf, N ;

Gottschalk, FA ;

Pak, CYC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1294-1301

[4]

POTTS JT, 1974, DUNCANS DIS METABOLI, P904

[5] Mechanism of osteoclast mediated bone resorption -: rationale for the design of new therapeutics [J].

Väänänen, K .

ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (07) :959-971

← 1 →